CHAPTER 4 REFERENCES

CHAPTER 4 REFERENCES

Abbas D, et al. Acceptability of an outpatient regimen of medical abortion with mifepristone and 800 mcg misoprostol administered buccally or sublingually at 71-84 days of gestation: a series of exploratory studies. Contraception. 2014 May;89(5):480. http://bit.ly/2G6al99

Aiken ARA, Digol I, Trussel J, Gomperts R. Self Reported Outcomes and Adverse Events After Medical Abortion Through Online Telemedicine: Population Based Study in the Republic of Ireland and Northern Ireland. BMJ. 2017 May 16;357:j2011. https://bit.ly/2X4Kl7u

Ashok, PW, Penney GC, Flett GMM, Templeton, A. An effective Regimen for Early Medical Abortion:  A Report of 200 Consecutive Cases. Hum Reprod 1998;13:2962-2965.  http://goo.gl/XWLvH

Blum J, et al. Comparison of misoprostol-only and combined mifepristone-misoprostol regimens for home-based early medical abortion in Tunisia and Vietnam. Int J Gynaecol Obstet. 2012;118:166-71. https://bit.ly/3enUIsU

Boersma AA, Meyboom-de Jong B, Kleiverda G. Mifepristone followed by home administration of buccal misoprostol for medical abortion up to 70 days of amenorrhoea in a general practice in Curaçao. Eur J Contracept Reprod Health Care. 2011 Apr;16(2):61-6. http://goo.gl/tHwKax

Bracken H, et al. Alternatives to routine ultrasound for eligibility assessment prior to early termination of pregnancy with mifepristone–misoprostol. BJOG. 2011;118(1):17-23. https://bit.ly/3bSvQIj

Bracken H, et al. A two-pill sublingual misoprostol outpatient regimen following mifepristone for medical abortion through 70 days’ LMP: a prospective open-label trial. Contraception. 2014 Mar;89(3):181-6. http://goo.gl/ze0c6k

Brandi K, Woodhams E, White K O, Mehta P K. An exploration of perceived contraceptive coercion at the time of abortion. Contraception. 2018 Apr;97(4):329-334. https://bit.ly/2X2BXFu

Castillo P, et al. Does a repeat dose of 800 mcg misoprostol following mifepristone improve outcomes in the later first trimester?. In: 41st Annual NAF Meeting 2017, Montreal, Canada.

Chai J, Wong CY, Ho PC. A randomized clinical trial comparing the short-term side effects of sublingual and buccal routes of misoprostol administration for medical abortions up to 63 days’ gestation. Contraception. 2013 Apr;87(4):480-5. http://goo.gl/5MDxnW

Chen MJ, Creinin MD. Mifepristone with Buccal Misoprostol for Medical Abortion: A Systematic Review. Obstet Gynecol. 2015 Jul;126(1):12-21. http://bit.ly/2NFIHEf

Chong E, et al. A Prospective, Non-Randomized Study of Home Use of Mifepristone for Medical Abortion in the U.S. Contraception. 2015 Sep;92(3):215-9. http://bit.ly/3690QjW

Clark W, et al. Medication abortion employing routine sequential measurements of serum hCG and sonography only when indicated. Contraception. 2007 Feb;75(2):131-5. https://bit.ly/2X9HE4U

Creinin MD, et al.  A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion.  Obstet Gynecol 2004 May;103(5 Pt 1):851-859.  http://goo.gl/EnwDD

Creinin MD, et al. Mifepristone antagonization with progesterone to prevent medical abortion: a randomized controlled trial. Obstet Gynecol. 2020 Jan; 135(1):158-165. https://bit.ly/2KiG2hr

Colwill AC, Bayer LL, Bednarek P, Gard B, Jensen JT, Edelman AB. Opioid Analgesia in Medication Abortion: A Randomized Control Trial. Obstet Gynecol 2019 Dec;134(6):1163-1170. https://bit.ly/2X44Tg5

Danco: FDA Package Label; Current Mifeprex materials March 2016. https://bit.ly/37HYECD

Dzuba IG, Castillo PW, et al. A repeat dose of misoprostol 800mcg following mifepristone for outpatient medical abortion at 64-70 and 71-77 days of gestation: A retrospective chart review. 2020 May. Contraception. 2020;S0010-7824(20)30160-8. https://bit.ly/2Z0htNr

Dzuba I, Chong E, Hannum C, et al. Outpatient mifepristone-misoprostol medical abortion through 77 days of gestation. 2016 Oct;94(4):389. http://bit.ly/2NFbjNW

Dzuba IG, et al. A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation. Contraception. 2020 May;101(5):302-308. https://bit.ly/2UPnvy8

Fiala C, et al. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003; 109: 190-195. https://bit.ly/2xQJ2il

Fjerstad M, et al. Severity of infection following the introduction of new infection control measures for medical abortion. Contraception. 2011 Apr;83(4):330-5.  http://goo.gl/PXlnh

Gatter M, Cleland K, Nucatola DL, Efficacy and safety of medical abortion using mifepristone and buccal misoprostol through 63 days. Contraception 2015 April 91(4): 269-73. http://goo.gl/lAK88G

Grossman D, Grindlay K. Alternatives to Ultrasound for Follow-up After Medication Abortion: A Systemic Review. Contraception. 2011; 83(6):504–510. https://bit.ly/2V3KC8f

Grossman D, et al. Effectiveness and acceptability of medical abortion provided through telemedicine. Obstet Gynecol. 2011 Aug;118(2 Pt 1):296-303. http://goo.gl/sPSaIJ

Grossman D, et al. Continuing pregnancy after mifepristone “reversal” of first-trimester medical abortion: a systematic review. Contraception. 2015 Sep;92(3):206-11. https://bit.ly/2ROWsTc

Gynuity Health Projects. Consensus Statement: Instructions for Use: Abortion Induction with Misoprostol Alone in Pregnancies Through 9 Weeks’ LMP. October 2013. http://bit.ly/378ShqT

Hamoda H, Ashok PW, Flett GM, Templeton A. Medical Abortion at 64 to 91 days of gestation: a Review of 483 Consecutive Cases. Am J Obstet Gynecol. 2003 May;188(5):1315-9. http://bit.ly/2TCgku9

Hamoda H, Ashok PW, Flett GM, Templeton Al. A Randomised Controlled Trial of Mifepristone in Combination with Misoprostol Administered Sublingually or Vaginally for Medical Abortion up to 13 Weeks gestation. BJOG. 2005 Aug;112(8):1102-8. https://bit.ly/2Vmqhwr

Hollenbach SJ, et al. “Provoked” feto-maternal hemorrhage may represent insensible cell exchange in pregnancies from 6 to 22 weeks gestational age. Contraception. 2019 Aug;100(2):142-146. https://bit.ly/2JERDqK

Horvath S, et al. The concentration of fetal red blood cells in first-trimester pregnant women undergoing uterine aspiration is below the calculated threshold for Rh sensitization. Contraception 2020. https://bit.ly/2wjmDty

Hsia JK, Lohr PA, Taylor J, Creinin MD. Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days’ gestation. Contraception. 2019;100(3):178-81. https://bit.ly/39rUSwp

Ipas Clinical Updates in Reproductive Health: Recommendations for abortion before 13 weeks gestation, Medication abortion. Published 2020. https://bit.ly/2xx45X2

Jones RK, WitwerE, Jerman J. Abortion Incidence and Service Availability in the United States, 2017. New York: Guttmacher Institute, 2019. http://bit.ly/3akfPLk

Kapp N, Eckersberger E, Lavelanet A, Rodriguez MI. Medication Abortion in the Late First Trimester: A Systematic Review. Contraception. 2019 Feb;99(2):77-86. https://bit.ly/2UMeu9e

Kavanaugh M, et al. Patients’ attitudes and experiences related to receiving contraception during abortion care.  Contraception. 2011; 84; 583-593. https://bit.ly/3dsGmrb

Kulier R, Kapp N, Gulmezoglu A M, et al. Medical methods for first trimester abortion. Cochrane Database Syst Rev. 2011 Nov 9;2011(11):CD002855. https://bit.ly/2X2GR5a

Larsson A, Rönnberg AM. Expanding a woman’s options to include home use of misoprostol for medical abortion up until 76 days: an observational study of efficacy and safety. Acta Obstet Gynecol Scand. 2019; 98747-752. https://bit.ly/39o1Nqd

Lokeland M, Iverson OE, Dahle GS, Nappen MH, Ertzeid L, Bjorge L. Medical abortion at 63 to 90 days of gestation. Obstetrics & Gynecology. 2010 May;115(2), 962-968. https://bit.ly/2UIBtBW

Matulich M, et al. Understanding women’s desires for contraceptive counseling at the time of first-trimester surgical abortion. Contraception. 2014; 89; 36-41. https://bit.ly/3ey1dt7

Mark A, Foster A, Grossman D, et al. Forgoing Rh testing and anti-D immunoglobulin for women presenting for early abortion: a recommendation from the National Abortion Federation’s Clinical Policies Committee. Contraception. 2019 May;99(5):265-266. http://bit.ly/2RvmdqB

Meites E, Zane S, Gould C; C. sordellii Investigators. Fatal Clostridium sordellii infections after medical abortions. N Engl J Med. 2010 Sep 30;363(14):1382-3. https://bit.ly/3hNkt8a 

Middleton T, Schaff E, Fielding SL, et al. Randomized trial of mifepristone and misoprostol for abortion through 56 days of LMP. Contraception 2005;72:328-332.  http://goo.gl/hGXes

Moreno-Ruiz NL, Borgatta L, Yanow S, Kapp N, Wiebe ER, Winikoff B. Alternatives to Mifepristone for Early Medical Abortion. Int J Gynaecol Obstet. 2007 Mar;96(3):212-8. http://bit.ly/2TEBwzW

Murtagh C et al. Exploring the feasibility of obtaining mifepristone and misoprostol from the internet. Contraception. 2017; 92: 297-301. https://bit.ly/2xuTf3I

National Abortion Federation Clinical Policy Guidelines 2020. https://bit.ly/2vYzyB1

Oppegaard KS, Qvigstad E, Fiala C, Heikinheimo O, Benson L, Gemzell-Danielsson K. Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial. Lancet. 2015 Feb 21;385(9969):698-704. http://goo.gl/fTxe2V

Perriera LK.  Reeves MF, Chen BA, Hohmann HL, Hayes J, Creinin MD. Feasibility of telephone follow-up after medical abortion. Contraception 2010; 81: 143-149. https://bit.ly/2xU0guV

Pocius KD, et al. Serum human chorionic gonadotropin (hCG) trend within the first few days after medication abortion: a prospective study. Contraception. 2016 Mar; 95 (3): 263-68. https://bit.ly/3bm7qY2

Raymond E, et al. TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States. Contraception. 2019;100:173-177. https://bit.ly/2U07o1k

Raymond EG, et al. No-Test Medication Abortion: A Sample Protocol for Increasing Access During a Pandemic and Beyond. Contraception. 2020 Apr; epub ahead of print. https://bit.ly/3bluPZA

Raymond EG, et al. Simplified medical abortion screening: a demonstration project. Contraception. 2018 Apr;97(4):292-296. https://bit.ly/36CAdGg

Raymond EG, et al. Effects of DMPA Injection Timing on Medical Abortion Efficacy and Repeat Pregnancy: An RCT. Obstet Gynecol. 2016 Oct;128(4):739-45. http://bit.ly/2G2yeOL

Raymond EG, Weaver MA, Tan YL, et al. Effect of Immediate Compared With Delayed Insertion of Etonogestrel Implants on Medical Abortion Efficacy and Repeat Pregnancy: A Randomized Controlled Trial. Obstet Gynecol. 2016 Feb;127(2):306-12. http://goo.gl/ML5XId

Reeves MF, et al. Endometrial Thickness Following Medical Abortion Is not Predictive of Subsequent Surgical Intervention. Ultrasound Obstet Gynecol. 2009;34(1):104-9. http://goo.gl/nWW3Al

Reeves MF, Kudva A, Creinin MD. Medical abortion outcomes after a second dose of misoprostol for persistent gestational sac. Contraception. 2008 Oct;78(4):332-5. http://goo.gl/NdEyFD

Reeves MF, Monmaney JA, Creinin MD. Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol. Contraception. 2016 Feb;93(2):119-25. http://goo.gl/Fvh0Fg

Sääv I, et al. Early versus delayed insertion of intrauterine contraception after medical abortion – a randomized controlled trial. PLoS One. 2012;7(11):e48948. http://goo.gl/5o3Uk8

Sanhueza Smith P, Peña M, Dzuba IG, et al. Safety, efficacy and acceptability of outpatient mifepristone-misoprostol medical abortion through 70 days since last menstrual period in public sector facilities in Mexico City. Reprod Health Matters. 2015 Feb;22(44 Suppl 1):75-82. http://goo.gl/QXEZnA

Schaff EA, Eisinger SH, Stadalius LS, Franks P, Gore BZ, Poppema S.  Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.  Contraception 1999 Jan;59(1):1-6.  http://goo.gl/jzk3F

Schaff EA, et al.  Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy. Contraception 2002 Oct;66(4):247-250. http://goo.gl/LMcUJ

Schmidt-Hansen M, et al. Follow-up Strategies to Confirm the Success of Medical Abortion of Pregnancies Up to 10 Weeks’ Gestation: A systematic Review with Meta-Analysis. Am J Obstet Gynecol. 2019 Nov 9. pii: S0002-9378(19)32615-8. http://bit.ly/2TFjoFS

Schonberg D, et al. The accuracy of using last menstrual period to determine gestational age for first trimester medication abortion: a systematic review. Contraception. 2014;90:480-7. https://bit.ly/2VCLj96

Seeber BE, Barnhart KT. Suspected ectopic pregnancy. Obstet Gynecol. 2006 Feb;107(2 Pt 1):399-413. Review. Erratum in: Obstet Gynecol. 2006 Apr;107(4):955. http://goo.gl/Li5tzr

SFP ACOG Practice bulletin no. 143: medical management of first-trimester abortion. Obstet Gynecol. 2014;123(3):676-692. https://bit.ly/2YOWLjv

Sheldon WR, Durocher J, Dzuba IG, Sayette H, Martin R, Velasco MC, Winikoff B. Early Abortion with Buccal vs Sublingual Misoprostol Alone: a Multicenter Randomized Trial. Contraception. 2019 May;99(5):272-277. http://bit.ly/368bvvt

Society of Family Planning Clinical Guideline. Medical management of first-trimester abortion. Contraception 89(3) 2014, pp. 148–161. http://goo.gl/BJiETT

Stillman M, et al. Women’s self-reported experiences using misoprostol obtained from drug sellers: a prospective cohort study in Lagos State, Nigeria. BMJ Open. 2020;10:e034670. https://bit.ly/2TK4AVX

Tang OS, Chan CC, Ng EH, Lee SW, Ho PC. A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation. Hum Reprod. 2003 Nov;18(11):2315-8. http://goo.gl/RMgL5k

Tang OS, Xu J, Cheng L, Lee SW, Ho PC. The effect of contraceptive pills on the measured blood loss in medical termination of pregnancy by mifepristone and misoprostol: a randomized placebo controlled trial. Hum Reprod. 2002;17:99–102. https://bit.ly/2RcGMsw

Von Hertzen H, et al. Misoprostol dose and route after mifepristone for early medication abortion: a randomized controlled noninferiority trial. BJOG. 2010 Aug; 117:1186-1196. https://bit.ly/2ZFBOJV

Von Hertzen H, Piaggio G, Huong NT, et al. Efficacy of two intervals and two routes of administration of misoprostol for termination of early pregnancy: a randomised controlled trial. Lancet. Jun 9 2007;369(9577):1938-1946. http://goo.gl/P7xGtI

Winikoff B, Dzuba IG, Chong E, et al. Extending outpatient medical abortion services through 70 days of gestational age. Obstet Gynecol. 2012 Nov;120(5):1070-6. http://goo.gl/cLx0eM

World Health Organization. Medical Management of Abortion. Geneva, 2018. http://bit.ly/2sz9ieC

License

EARLY ABORTION TRAINING CURRICULUM Copyright © 2020 by UCSF Bixby Center for Global Reproductive Health. All Rights Reserved.